MedPath

The effect of a novel polysaccharide blend (PGX® micro-granules) on short- term weight loss and other laboratory parameters in overweight and obese adults: an observational retrospective analysis

Not Applicable
Conditions
Overweight/obesity
Nutritional, Metabolic, Endocrine
Obesity
Registration Number
ISRCTN50749194
Lead Sponsor
Factors Group of Nutritional Companies Inc. (Canada)
Brief Summary

Results article in https://pubmed.ncbi.nlm.nih.gov/20359270/ (added 19/07/2021)

Detailed Description

Not available

Recruitment & Eligibility

Sex
Not specified
Target Recruitment
29
Inclusion Criteria

1. 20 to 65 year of age
2. Body mass index range of approximately 23 kg/m^2 to 35 kg/m^2
3. Otherwise healthy

Exclusion Criteria

1. Morbid obesity
2. Major psychiatric diagnosis
3. Use of other weight loss medications such as sibutramine or ephedra

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcomes measured for all participants are weight (pounds), waist and hip circumference, and percent body fat. Percent body fat was determined using bioelectrical impedance testing at baseline and every two weeks thereafter.
Secondary Outcome Measures
NameTimeMethod
All subjects enrolled in the program were initially evaluated for High Density Lipoprotein (HDL), LDL, total cholesterol, triglycerides, fasting glucose, fasting insulin, two hour fasting insulin, and 75 gram glucose tolerance test at baseline, only those with aberrant risk factors were re-tested using the latter laboratory parameters at week 14.
© Copyright 2025. All Rights Reserved by MedPath